Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

State Funding Changes in Spotlight in U.S. Republican Healthcare Bill

Susan Heavey & Yasmeen Abutaleb  |  September 22, 2017

WASHINGTON (Reuters)—Republican leaders sought to nail down the final votes needed to pass what U.S. Vice President Mike Pence on Thursday called their “last best chance” to repeal Obamacare while a new analysis underscored how Democratic-leaning states stand to lose large amounts of federal funding under the legislation. Senate Majority Leader Mitch McConnell (R-Ky.) plans…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)Graham-Cassidy AmendmentHealth InsuranceObamacare repealObamacare repeal legislation

Inflammatory Spinal Disorders Common in IBD Patients

Anne Harding  |  September 21, 2017

NEW YORK (Reuters Health)—Ankylosing spondylitis (AS), axial spondyloarthritis (SpA) and inflammatory back pain are common in inflammatory bowel disease (IBD) patients two decades after IBD diagnosis, according to findings from the IBSEN study1. Doctors should know IBD patients are at risk of inflammatory back problems, and refer them to a rheumatologist when appropriate, Dr. Alvilde Ossum…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing Spondylitisaxial spondyloarthritis (SpA)inflammatory back paininflammatory bowel disease (IBD)Inflammatory Bowel South-Eastern Norway studyinflammatory spinal disorders

Pfizer Files Suit Against J and J over Remicade Contracts

Caroline Humer  |  September 20, 2017

(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…

Filed under:Legal Updates Tagged with:Johnson and JohnsonlawsuitPfizer Inc.REMICADE (infliximab)

Unbudgeted: How the Opioid Crisis Is Blowing a Hole in Small-Town America’s Finances

Paula Seligson & Tim Reid  |  September 20, 2017

INDIANA, Pa./CHILLICOTHE, Ohio (Reuters)—As deaths mount in America’s opioid crisis, communities on the front lines face a hidden toll: the financial cost. Ross County, a largely rural region of 77,000 people an hour south of Columbus, Ohio, is wrestling with an explosion in opioid-related deaths—44 last year compared with 19 in 2009. The drug addiction…

Filed under:AnalgesicsDrug Updates

U.S. Democrats Urge Full Review Before Senate Vote on Latest Obamacare Attack

Susan Cornwell  |  September 20, 2017

WASHINGTON (Reuters)—Democratic leaders in the U.S. Congress on Monday demanded that lawmakers wait to find out the budgetary and healthcare impacts of a new, last-ditch legislative effort by Republicans to repeal Obamacare before voting on it. In their long-running war on former President Barack Obama’s signature healthcare law, Senate Republicans are now proposing to replace…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)Health InsuranceObamacareU.S. Senate health bill

TNF Inhibitor Drug Tapering Successful in Some Patients with RA

Thomas R. Collins  |  September 19, 2017

MADRID—Scores on the Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ) and C-reactive protein (CRP) levels were independent predictors of whether patients could be tapered successfully from a TNF inhibitor after having reached remission of their RA, according to findings presented in a session at the Annual European Congress of Rheumatology. Researchers also developed a composite…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:adalimumabAnnual European Congress of RheumatologyClinicaldrugetanerceptEULARglucocorticosteroidMedicationoutcomeResearchRheumatoid arthritistaperingtherapyTNF inhibitorTreatment

Rheumatoid Arthritis Treatments Show Mixed Results

Thomas R. Collins  |  September 19, 2017

MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX) and compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). The drug missed its primary endpoint…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Annual European Congress of Rheumatologyanti-IL6ClinicalDisease-modifying antirheumatic drugs (DMARDs)drugEULARMedicationMethotrexatenanobodyoutcomeRheumatoid arthritisrheumatologistrheumatologyTreatmentvobarilizumab

Skype-Based Biopsychosocial Treatments Help Save Physical Therapy Patients Time, Trouble

Elizabeth Hofheinz, MPH, MEd  |  September 19, 2017

It’s a bit ironic that when injured people are in pain—and their mobility is reduced—they are often expected to travel to a physical therapy clinic. For millions of people, such trips are a burden. In Australia, however, some patients are “letting movement come to them.” Novel research from The University of Melbourne shows that taking…

Filed under:Practice SupportResearch RheumTechnology Tagged with:biopsychosocialExerciseInternetonlinePain Managementpatient carePhysical TherapyPractice ManagementResearchstudyTreatment

A CT scan of the chest showing multifocal ground-glass opacities, representative of hemorrhage, with numerous nodular interstitial opacities primarily within a peribronchovascular distribution.

Hemoptysis in a Young Indian Male

Payam Pourhassani, DO, MSc, Sneha Patel, MD, & Arundathi Jayatilleke, MD  |  September 19, 2017

A 22-year-old Indian male presented to the emergency department with hemoptysis. A month prior, he had presented to an urgent care center complaining of cough with occasional episodes of blood-tinged sputum in the morning. He was diagnosed with community-acquired pneumonia based on a chest X-ray without laboratory testing and was prescribed levofloxacin. A few days…

Filed under:ConditionsVasculitis Tagged with:bronchoalveolar lavageClinicalCT scanDiagnosisdiffuse alveolar hemorrhagegranulomatosis with polyangiitishemoptysisMRImultisystem diseasepatient carerheumatologistrheumatologysymptomTestVasculitis

FDA Approves Lesinurad + Allopurinol

Michele B. Kaufman, PharmD, BCGP  |  September 19, 2017

Duzallo, a combination of lesinurad and allopurinol, was approved by the FDA in August to treat hyperuricemia associated with gout…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:AllopurinolDuzalloFDAFood and Drug AdministrationGouthyperuricemialesinuradU.S. Food and Drug Administration

  • « Previous Page
  • 1
  • …
  • 173
  • 174
  • 175
  • 176
  • 177
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences